About us
Who we are
BioNukleo GmbH, founded in 2014 as a spin-off from the Chair of Bioprocess Engineering at the Technical University of Berlin, draws on years of academic research in enzymatic nucleoside and nucleotide production and the expression of challenging proteins. As a privately held company, we combine academic expertise with entrepreneurial innovation to tackle the complex challenges in our industry.
Since our founding, BioNukleo has established itself as a specialist in biocatalysis, focusing on the synthesis of nucleoside and nucleotide derivatives, as well as other related fine chemicals. Our dedication to research and development in the field of applied biocatalysis enables us to create effective and sustainable solutions that meet the evolving needs of our clients.
Our team is a dynamic group of passionate scientists and engineers, blending youthful agility with a commitment to scientific excellence. We focus on researching and developing innovative technologies tailored to our customers' specific needs. Our strength lies not only in the quality of our products but also in our flexible and responsive approach to rapidly changing market demands. We value a creative and inspiring corporate culture that empowers us to deliver customized, cutting-edge solutions.
Location
BioNukleo is located in Berlin, Germany's vibrant capital known for its rich culture and high quality of life. The city boasts a strong concentration of research institutions and clinics, making it a leading hub for healthcare and life science innovation. With over 500 biotech, pharma, and medtech companies, the region benefits from a highly qualified workforce and excellent networking opportunities.
Situated on the Technische Universität Berlin campus in Wedding, BioNukleo thrives in a dynamic research environment, facilitating partnerships and access to specialized facilities and expertise.
We are easily accessible via public transportation: bus 247 (to Gartenplatz), tram M10 (to Gedenkstätte Berliner Mauer), subway U8 (to Voltastraße), and interurban trains S1, S2, S25, S26 (to Nordbahnhof/Humboldthain).
Founding Members
Anke Kurreck
CEO
- Dr. rer. nat. with a focus on Microbiology
- Over 15 years of scientific experience in environmental microbiology, RNA interference (RNAi) applications, and biochemistry
- More than 7 years of experience in expressing difficult-to-express proteins and process development for customer projects
- Author of over 40 publications in peer-reviewed journals
- Successfully managed over 10 funding projects
- Board member of the NetPhaSol network
Maryke Fehlau
CTO
- Dr.-Ing. with a focus on Biocatalysis
- Over 10 years of experience in biocatalysis, including biocatalyst identification, multi-enzyme cascade design, and the establishment of analytical methods and product purification strategies
- More than 7 years of experience in process development for customer projects
- Specialist in nucleotide products
Advisory Board
Prof. Dr. Peter Neubauer
Head of the Chair of Bioprocess Engineering, TU Berlin
- Dr. rer. nat. in Microbiology and Bioprocess Development
- Over 30 years of experience in the biotechnology sector
- More than 350 publications in microbiology, bioprocess engineering, automation, high-throughput processes, and process analytical technology
- Active member of various scientific societies and associations, including Dechema and the BioProScale Association
- Serial entrepreneur with a track record of successful ventures
- Honored with multiple awards, including the prestigious Agilent Thought Leader Award
Prof. Dr. Jens Kurreck
Head of the Chair of Applied Biochemistry, TU Berlin
- Dr. rer. nat. with a focus on Biochemistry and Medical Biotechnology
- 25 years of experience in biotechnology
- Author of 120 publications in RNA technologies, virology, cancer research, bioprinting, and organ models
- Active member of various scientific societies and associations, including GBM and EUSAAT; co-speaker at the Einstein Center 3R
- Advisor and mentor for spin-off companies
- Recipient of several awards, including the Herbert-Stiller Prize for human-relevant research without animal experiments and the Prize of the State of Berlin for promoting alternative and supplementary methods in animal research
